Jazz Pharms Res Drug Patent Portfolio
Jazz Pharms Res owns 1 orange book drug protected by 32 US patents Given below is the list of Jazz Pharms Res's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160795 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | 01 Mar, 2041 | Active |
| US11406623 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus | 01 Mar, 2041 | Active |
| US11207292 | Cannabidiol preparations and its uses | 26 Apr, 2039 | Active |
| US11865102 | Cannabidiol preparations and its uses | 26 Apr, 2039 | Active |
| US10918608 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11065209 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11096905 | Use of cannabinoids in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US11400055 | Use of cannabidiol in the treatment of epilepsy | 13 Oct, 2035 | Active |
| US10092525 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10111840 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10137095 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10603288 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709671 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709673 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10709674 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10849860 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10966939 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11154516 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11311498 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11357741 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11446258 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11633369 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11701330 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11766411 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US11963937 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US12064399 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9949937 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956183 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956184 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956185 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US9956186 | Use of cannabinoids in the treatment of epilepsy | 17 Jun, 2035 | Active |
| US10195159 | Processes and apparatus for extraction of active substances and enriched extracts from natural products | 07 May, 2022 | Expired |
Latest Legal Activities on Jazz Pharms Res's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Jazz Pharms Res.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US10918608 |
|
Email Notification
Critical
| 21 Jun, 2024 | US10709673 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US11096905 |
|
Email Notification
Critical
| 21 Jun, 2024 | US11406623 |
|
Email Notification
Critical
| 21 Jun, 2024 | US9956184 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US10092525 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US9956184 |
|
Email Notification
Critical
| 21 Jun, 2024 | US10092525 |
|
Email Notification
Critical
| 21 Jun, 2024 | US11096905 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US11406623 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Jun, 2024 | US10709673 |
|
Email Notification
Critical
| 18 Jun, 2024 | US9956185 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Jun, 2024 | US9956185 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 17 Jun, 2024 | US10137095 |
|
Email Notification
Critical
| 17 Jun, 2024 | US10709671 |
Jazz Pharms Res Drug Patents' Oppositions Filed in EPO
Jazz Pharms Res drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 29, 2021, by James Poole Limited. This opposition was filed on patent number EP15784111A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP15784111A | Apr, 2021 | James Poole Limited | Granted and Under Opposition |
Jazz Pharms Res's Family Patents
Jazz Pharms Res drugs have patent protection in a total of 25 countries. It's US patent count contributes only to 25.1% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Jazz Pharms Res Drug List
Given below is the complete list of Jazz Pharms Res's drugs and the patents protecting them.
1. Epidiolex
Epidiolex is protected by 32 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11160795 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
01 Mar, 2041
(16 years from now)
| Active |
| US11406623 | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
01 Mar, 2041
(16 years from now)
| Active |
| US11207292 | Cannabidiol preparations and its uses |
26 Apr, 2039
(14 years from now)
| Active |
| US11865102 | Cannabidiol preparations and its uses |
26 Apr, 2039
(14 years from now)
| Active |
| US10918608 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(10 years from now)
| Active |
| US11065209 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(10 years from now)
| Active |
| US11096905 | Use of cannabinoids in the treatment of epilepsy |
13 Oct, 2035
(10 years from now)
| Active |
| US11400055 | Use of cannabidiol in the treatment of epilepsy |
13 Oct, 2035
(10 years from now)
| Active |
| US10092525 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10111840 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10137095 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10603288 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10709671 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10709673 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10709674 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10849860 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10966939 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11154516 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11311498 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11357741 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11446258 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11633369 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11701330 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11766411 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US11963937 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US12064399 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US9949937 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US9956183 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US9956184 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US9956185 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US9956186 | Use of cannabinoids in the treatment of epilepsy |
17 Jun, 2035
(10 years from now)
| Active |
| US10195159 | Processes and apparatus for extraction of active substances and enriched extracts from natural products |
07 May, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epidiolex's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List